Patient demographics and baseline characteristics for the ATTRACTION-2 HPD analysis population
| Characteristic | Placebo (n=115) | Nivolumab 3 mg/kg (n=243) |
| Age, years, median (range) | 61 (26–83) | 63 (20–83) |
| Female, n (%) | 28 (24.4) | 60 (24.7) |
| Race, n (%) | ||
| Asian | 115 (100.0) | 242 (99.6) |
| Native Hawaiian/other Pacific Islander | 0 | 1 (0.4) |
| ECOG PS, n (%) | ||
| 0 | 28 (24.4) | 64 (26.3) |
| 1 | 71 (61.7) | 161 (66.3) |
| Baseline tumor size, cm | ||
| Mean (SD) | 7.9 (5.1) | 8.2 (5.8) |
| Median (range) | 6.6 (1.3–25.3) | 6.7 (1–31.3) |
ECOG PS, Eastern Cooperative Oncology Group performance status; HPD, hyperprogressive disease.